MedTrace Logo

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

NCT05611905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2025-12-12

No results posted yet for this study

Summary

The investigators will perform radionuclide PET scans in subjects with infectious diseases to assess whether radio-labeled PABA (11C-PABA) is effective for infection imaging.

Tomographic imaging can be used to evaluate disease processes deep within the body, noninvasively and relatively rapidly. The goal is to see if this imaging technique can help differentiate infections from non-infectious processes and also provide information on the causative bacterial class.

Conditions

Interventions

COMBINATION_PRODUCT

11C-para-aminobenzoic acid PET/CT

A bolus of 20 mCi of 11C-PABA followed by PET/CT

DRUG

Probenecid

Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.

Sponsors & Collaborators

Principal Investigators

  • Sanjay K Jain, MD · Johns Hopkins University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-22
Primary Completion
2025-11-08
Completion
2025-11-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05611905 on ClinicalTrials.gov